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ABSTRACT 
 
Prostate cancer (Pca) is the number one cancer in U.S. men and a leading cause of 
cancer-related deaths. The disease is initially dependent upon active male androgens for 
survival, such as testosterone or dihydrotestosterone. However, relatively inactive 
androgens like 5-androstenediol (5Adiol) have been considered to play larger roles in 
disease progression than previously considered. 5Adiol is synthesized in the prostate, is 
not affected by current anti-androgen therapies, and activates the androgen receptor in 
human prostate cancer cell lines more effectively than active male androgens.  
 
The causal relationship between androgens and prostate cancer progression has 
significantly risen due to anabolic steroid abuse in competitive sports and recreational 
athletes. The evidence surrounding an association between androgen abuse and prostate 
cancer, as well as various other carcinomas, is of great concern within this demographic 
because of its preventability. Despite their prohibited use, anabolic products continue to 
be marketed and available for purchase as nutritional supplements. Surveys on current 
steroid user trends have documented high dosing regimens, extended periods of use, 
multiple self-diagnosed side effects, and unsafe injection practices.  
 
Because few studies have investigated the effects of advertised 5Adiol products on 
prostate cancer progression, the goal of this study was to investigate whether Value 
Nutrition’s 5Adiol product possesses comparable mitogenic stimulant activity to 
testosterone in the androgen-dependent cell line, LNCaP. It should be noted that while 
this compound is banned by the U.S. Drug Enforcement Administration and is no longer 
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sold through this company, alternative steroids continue to be marketed to consumers. 
Additional goals included determining whether this product would affect the proliferation 
of liver cells using the HepG2 cell line, if HepG2 metabolism of the product would play a 
role in the proliferation of LNCaP cells, and whether the LNCaP cells are capable of 
converting the 5Adiol product into testosterone. Multiple assays determined that the 
LNCaP cells were androgen responsive to the 5Adiol product, HepG2 proliferation was 
stimulated, and HepG2 metabolism of the 5Adiol product increased LNCaP mitogenicity, 
although significant differences were unattainable primarily due to the LNCaP cells 
reduced adhesion properties. Because reverse-phase HPLC was unable to detect 
compounds within 5Adiol even at high concentrations, the mitogenicity observed in both 
cell lines is unable to be correlated with a particular component in this product. While it 
is possible that 5Adiol is present at extremely low levels, contamination with other 
factors, hazardous or not, cannot be ruled out. In conclusion, these results suggest that the 
use of nutraceuticals have inherent risks for men at risk of developing prostate cancer. 
The mitogenic effects observed from small levels of unknown compounds in the tested 
5Adiol product raise serious questions as to the legitimacy of allowing companies to 
market and self-regulate their own products. 
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INTRODUCTION 
 
Prostate Cancer 
Prostate cancer (Pca) is the single most commonly diagnosed cancer in men in the United 
States, as well as a leading cause of cancer-related deaths. In the year 2007 alone, the 
American Cancer Society estimates 218,890 new cases and 27,050 deaths [Society, 
2007]. Pca is an incomparable cancer not only due to its morbidity but also because of the 
mortality rate associated with it [Claudio et al., 2002]. In a majority of cases, prostate 
cancer is diagnosed as an androgen-dependent carcinoma initially combated with 
neoadjuvant therapy or prostatectomy surgery, if possible [Dehm and Tindall, 2006; Kent 
and Hussain, 2003]. If either fails to effectively fight the cancer, castration and androgen 
ablation therapy are employed, both of which aim to reduce/eliminate circulating 
androgens (C-19 sexual hormones responsible for masculinizing effects in the body), 
while ablation therapy also attempts to block the transcriptional activity of the androgen 
receptor (AR) [Dehm and Tindall, 2006; Heinlein and Chang, 2004; Kent and Hussain, 
2003]. However, in almost all patients with metastatic or locally expansive disease, 
which is usually associated with poor differentiation, the cancer relapses as an untreatable 
adenocarcinoma that no longer relies upon androgens for its survival and development, 
ultimately resulting in death [Dehm and Tindall, 2006; Kent and Hussain, 2003]. Even if 
caught early, many cases have been observed to progress into a systemic untreatable 
malignancy [Kent and Hussain, 2003]. 
 
 
 
Summary of Common In-Text Abbreviations: 
 
Pca: prostate cancer                       AR: androgen receptor 
5Adiol: 5-Androstenediol                     T: testosterone 
DHEA: dehydroepiandrosterone         DHT: dihydrotestosterone 
PSA: prostate specific antigen         AAS: androgenic-anabolic steroid 
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Physiological Role of Androgens in the Prostate  
All steroidal hormones contain a core structure characterized by a 
cyclopentanoperhydrophenanthrene nucleus, which contains three cyclohexane rings 
attached to one cyclopentane ring, designated A, B, C, and D (left to right) (Figure 1).  
 
 
Figure 1. Cyclopentanoperhydrophenanthrene nucleus of steroid structure [Hadley, 1996]  
(Figure obtained from Endocrinology text, 4th edition, by Mac E. Hadley in 1996; see references for full 
citation). 
 
The biological activity of steroids is conferred by a double bond between carbons 4 and 5 
(C4 and C5) and a ketone group located at C3, both found within the A ring of the core 
nucleus (Figure 2).  
 
Figure 2. Structure of testosterone [Hadley, 1996]. 
Note the ketone group off C3 and the double bond at C4 which bestow biological activity to the molecule 
(Figure obtained from Endocrinology text, 4th edition, by Mac E. Hadley in 1996; see references for full 
citation). 
 
Within the testes, androgen production occurs via an intricate and complex enzymatic 
process. Cholesterol and extracellular low-density lipoproteins are the major primary 
substrates for androgen synthesis within the Leydig cells [Hadley, 1996; Tentori and 
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Graziani, 2007]. The primary synthetic step in hormone production in the testes is the 
conversion of cholesterol to pregnenolone where the alkyl chain off of C17 is cleaved 
from the molecule (Figure 3). Dehydroepiandrosterone (DHEA), the most abundantly 
produced adrenal steroid, is then synthesized through the modification of C17 to form a 
ketone group. DHEA can then be metabolized to androstenedione or 5-androstenediol 
(5Adiol). Either of these metabolites can serve as substrates for testosterone (T) 
production.  Testosterone can be converted to dihydrotestosterone (DHT) (Figure 3), the 
most biologically active androgen in the male body [George, 1997; Mizokami et al., 
2004; Tentori and Graziani, 2007; Zhu et al., 2003]. 
 
Figure 3. Biochemical pathway of androgen synthesis [Mitamura et al., 2002]. 
List of abbreviations: DHEA, dehydroepiandrosterone; AD, androst-4-ene-3,17-dione; A-diol, androst-5-
ene-3β,17β-diol; T, testosterone; A, androsterone; DHT, 5α-dihydrotestosterone (Figure obtained from 
published data in 2002 paper by Mitamura et al; see references for full citation). 
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With respect to the male anatomy, androgen synthesis occurs within the smooth 
endoplasmic reticulum of cells within the adrenal glands or gonads, with a much greater 
production occurring in the latter. In men, the testes are the primary source of androgens. 
Among their many functions, androgens control the anatomical and physiological 
development of the male urogenital system, sexual development and maturity, production 
and maintenance of secondary sex characteristics, and even play roles in fat metabolism, 
brain function, and bone and immune health [Hadley, 1996; Hartgens and Kuipers, 2004].  
Specifically, T, the principle androgen in men, is endogenously produced and secreted by 
Leydig cells of the testes (an interstitial cell type) [Soronen et al., 2004]. Within the 
human body, only 2-3% of blood T is active in an unbound form [Mottram and George, 
2000]. The remaining T is bound to sex hormone binding protein (SHBP) in an inactive 
state. In the adult male and female body, physiological blood plasma levels of T are 
approximately 0.6 μg/dl (~20mM) and 0.3 μg/dl (~10 mM), respectively [Mottram and 
George, 2000]. Physiological levels of DHT range between 0.8-4.1 nM [Horoszewicz et 
al., 1983]. 
 
In target tissues like the prostate gland, whose primary function is to produce seminal 
fluid for ejaculation, T is converted to DHT. Both androgens bind the androgen receptor 
(AR), but while T regulates sexual development, maintains libido, and sexual function, 
DHT plays a pivotal role in embryonic & pubertal external virilization [Soronen et al., 
2004]. Furthermore, although T is more abundant in the circulation, DHT is known to be 
the more potent ligand of the AR, with a higher binding affinity [George, 1997; 
Mizokami et al., 2004; Tentori and Graziani, 2007; Zhu et al., 2003]. DHT is also a more 
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metabolically active ligand compared to T due to a slower dissociation rate from the AR 
and its induction of a receptor conformation that more readily resists degradation 
[Heinlein and Chang, 2004]. FW George in 1997 determined not only that DHT was the 
primary androgen in the prostate of rats, but also that the differential expression of T 
compared to DHT may be explained by the expression of 5α-reductase, an enzyme that 
reduces T to DHT [George, 1997]. It appears as though cells express this enzyme as a 
mechanism to prevent T catabolism to less androgenically active steroids by the 17β-
hydroxysteroid dehydrogenases. 
 
Androgen Receptor: Mode of Androgenic Action and Prostate Cancer Development  
Androgens mediate their effects within cells and targeted tissues via signaling cascades 
initialized through ligand binding to the androgen receptor (AR). The AR is structurally 
characterized by four domains: a ligand-binding domain (LBD), a DNA-binding domain 
(DBD), a hinge region, and an amino-terminal domain. In addition to these four primary 
domains, the AR also contains two additional domains that function in its transcriptional 
activity, an N-terminal ligand-independent activation function-1 (AF) domain and a C-
terminal ligand-dependent AF-2 domain [Agoulnik and Weigel, 2006; Heinlein and 
Chang, 2004]. 
 
The androgen receptor is a 110 kDa phosphoprotein and member of the nuclear receptor 
transcription factor superfamily [Agoulnik and Weigel, 2006; Lamb et al., 2001]. It is a 
ligand-activated transcription factor located within the cytoplasm in an inactivated state 
(Figure 4). Upon activation, the AR separates from heat shock proteins, dimerizes, and 
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translocates to the nucleus. There it binds to androgen response elements (ARE’s) in the 
cellular DNA, thereby initiating various signaling cascades which influence cellular 
growth and proliferation [Agoulnik and Weigel, 2006; Heinlein and Chang, 2004; Lamb 
et al., 2001].  
 
Figure 4. Biological signaling cascade mediated by the AR within the prostate [Heinlein and Chang, 
2004]. 
Upon binding to its native ligands within the cytosol, the AR dissociates from heat-shock proteins to 
complex with AR coactivators (ARAs). The complex then translocates to the nucleus where it binds to 
ARE’s in the DNA to activate the transcription of androgen-regulated genes. Additional signaling pathways 
(Smad, MAPK, etc.) can also be stimulated by growth factors to phosphorylate the AR, which upregulates 
its activity (Figure obtained from published work by Heinlein & Chang in a 2004 review article; see 
references for full citation). 
 
Gene expression mediated by the AR is critical to prostate function, growth, and survival 
in both normal and malignant tissue [Balk, 2002; Dehm and Tindall, 2006]. Because 
androgenic activity is mediated through this receptor, the AR is a common target of 
androgen deprivation therapy [Agoulnik and Weigel, 2006; Balk, 2002]. AR functionality 
in Pca is supported by multiple studies using androgen-independent Pca; a form of Pca 
where androgen stimulation is sufficient but not required for proliferation and survival. In 
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androgen-independent Pca, the AR has been shown to be more stable in the absence of 
androgen compared to androgen-dependent Pca [Gregory et al., 2001]. This stability is 
associated with a hypersensitivity to a range of androgen concentrations which were four-
fold lower than those required to activate the AR in the androgen-dependent cell line, 
LNCaP [Gregory et al., 2001].  Furthermore, upregulated transcription of the AR has 
been observed in androgen-independent tumors compared with androgen-dependent 
tumors [Balk, 2002]. A pivotal study by Chen et al in 2004 demonstrated increases in AR 
mRNA and protein in human tumor xenografts containing androgen-independent tumors 
derived from their parental dependent line [Chen et al., 2004]. This group also 
demonstrated that the AR is necessary for the progression of hormone-dependence to 
independence using RNAi technology to knockdown AR expression in castrated mice. 
 
Role of Androgens in Prostate Cancer 
From the initial ground-breaking discoveries of Huggins and Hodges in 1941, it was 
learned that castration drastically reduces endogenous androgen levels, and more 
importantly, that androgens regulate Pca activity [Huggins and Hodges, 1972]. In 1983, 
Horoszewicz et al developed a stable human cell line, named LNCaP, to model prostatic 
carcinoma [Horoszewicz et al., 1983]. These cells were derived from a lymph node 
metastasis of a patient with Pca and have since become the paradigm for studying 
androgen-dependent Pca. They are characterized as having a mutated AR (T877A) which 
permits receptor binding promiscuity to both natural and unnatural ligands [Gregory et 
al., 2001; Miyamoto et al., 1998]. Horoszewicz’s group demonstrated that the LNCaP 
cell line not only expresses the AR, but is also mitotically responsive to androgens, 
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specifically DHT, in a dose-dependent manner [Horoszewicz et al., 1983]. Although 
attempting to prove a different aim, Lee et al also observed a dose-dependent 
proliferative response to DHT in the same cells [Lee et al., 1995]. In a more recent study 
by Arnold et al in 2005, the proliferation of LNCaP cells treated with either DHEA, T, 
DHT, and estradiol was stimulated in both a time- and dose-dependent manner for all 
androgens [Arnold et al., 2005].  
 
Within in vivo studies, testosterone administration in rats has been shown both to increase 
the serum T level as well as stimulate hyperproliferative lesions in the prostate [Angelsen 
et al., 1999]. An earlier study conducted in 1970 by Rosner and Macome demonstrated 
that human testes specimens obtained from men diagnosed with Pca were able to convert 
DHEA and pregnenolone into 5Adiol [Rosner and Macome, 1970]. Moreover, when 
incubated with 5Adiol, the testes were able to convert 5Adiol into T, which proves the 
ability of conversion to a more active steroid. Although rare, thirteen cases of Pca are 
reported to have been documented in patients receiving testosterone to combat symptoms 
of hypogonadism from Klinefelter syndrome [Bydder et al., 2007]. In one particular case, 
the patient’s serum T concentration was initially 2.1 nM with a prostate specific antigen 
(PSA) level of 1.7 μg/L. After seven years of T replacement therapy however, his T 
serum level had risen to 17 nM, the PSA level had elevated to 27.5 μg/L, and the patient 
was clinically diagnosed with prostatic adenocarcinoma [Bydder et al., 2007]. Finally, 
documented cases of Pca development in bodybuilders exist, such as that reported by 
Roberts and Essenhigh in 1986, where prostate adenocarcinoma was reported in a 
bodybuilder who had used anabolic steroids for 20 years [Roberts and Essenhigh, 1986]. 
 14
As previously mentioned, hormone-responsive Pca commonly recurs as a hormone-
independent growth after androgen ablation therapy. Androgens that are relatively less 
metabolically active are not direct targets of ablation therapy. However, because they can 
still be converted to those which possess greater androgenic activity, androgen 
conversion was examined in one of the more significant studies to date by Mitamura et al 
[Mitamura et al., 2002]. The main design was to incubate human prostate homogenate 
with dehydroepiandrosterone (DHEA), a less active androgen highly synthesized by the 
adrenal glands. Surprisingly, an androgen less focused upon in current literature, 5-
androstenediol (5Adiol), was found to be the primary metabolite of DHEA in the human 
prostate. 5Adiol is known to be endogenously synthesized from DHEA in multiple 
tissues, including the prostate epithelium, and physiological levels are estimated to be 
approximately 5.2 nM [Mizokami et al., 2004]. It had been previously demonstrated that 
5Adiol activity is not blocked by current anti-androgen therapeutics [Chang et al., 1999] 
and that it is capable of activating the AR in human Pca cells (LNCaP), [Miyamoto et al., 
1998] thereby indicating the importance of the findings from the Mitamura study.  
 
Coupled with the aforementioned studies, in 2004, 5Adiol was recently shown by 
Mizokami’s group to be a more potent activator of androgenic activity than DHT via the 
mutated AR in LNCaP cells [Mizokami et al., 2004]. This activation is not proposed to 
be mediated through the binding affinity since DHT has a three-fold higher affinity for 
the AR compared to 5Adiol (DHT: Kd = 0.58 nM; 5Adiol: Kd = 1.90 nM), but rather 
through an increased ability to translocate the AR to the nucleus where it acts as a 
transcriptional activator of hormone-responsive elements in the DNA. Furthermore, 
 15
5Adiol stimulated proliferation more effectively in the LNCaP cell line at a 10-fold lower 
concentration than either T or DHT [Mizokami et al., 2004]. Mizokami’s group also 
observed that while the concentration of DHT decreased in human Pca tissue samples 
after hormone therapy, as compared to tissue from patients with benign prostate 
hypertrophy, the levels of 5Adiol remained unchanged although measurements before 
therapy in the same patients had not been performed [Mizokami et al., 2004]. Providing 
validation to this finding, Higashi’s group in 2006 used liquid chromatography-mass 
spectroscopy to determine that the level of 5Adiol was unchanged amongst patients 
within three groups: those with benign prostate hypertrophy, Pca that had been treated 
with 3-6 months of androgen deprivation therapy, or bladder cancer treated by radical 
cystoprostatectomy [Higashi et al., 2006]. This is in comparison to DHT levels that were 
significantly lower in the Pca group versus the benign group, further indicating that 
5Adiol is an active androgen unaffected by conventional ablation therapies. In slight 
contrast to these studies are the results from Nishiyama’s lab in 2004 which analyzed Pca 
patient samples before and after anti-androgen therapy [Nishiyama et al., 2004]. It was 
found that after six months of therapy, DHT levels were approximately 25% of the pre-
therapeutic levels. Although levels were decreased, there is enough in the tissue to 
hypothetically sustain the cancer through therapy aimed at its destruction. This study also 
raises the question of developing additional drugs to target not only androgens, but the 
enzymes that are able to convert adrenal androgens to T or DHT in the prostate. 
 
 
 
 16
Androgenic-Anabolic Steroids (AAS): Elevated Risk of Prostate Cancer? 
Within the past sixty years, the role of androgens in Pca progression has become ever 
more compounded by steroid abuse. The use of performance enhancers was first 
documented during the 1950s in international weightlifting championships [Hartgens and 
Kuipers, 2004]. Since then androgens have been used abundantly by sport athletes 
(recreational and professional), bodybuilders, and high school students to accelerate 
muscle mass, enhance performance and strength, and improve appearance and self-
esteem [Hartgens and Kuipers, 2004; King et al., 1999; Mottram and George, 2000; 
Pallesen et al., 2006; Parkinson and Evans, 2006]. Although the use of most steroids and 
androgens without a prescription was banned in the United States through the 2004 
amendment of the Anabolic Steroid Control Act of 1990, anabolic products are still 
aggressively marketed and widely available for purchase. One reason for continued 
availability of anabolic steroids is linked to the 1994 Dietary Supplement Health and 
Education Act, which permits companies to sidestep regulations by the United States 
Food and Drug Administration as long as the products are not marketed to cure or 
prevent disease [Catlin et al., 2000]. This leads to many androgenic-anabolic steroids 
(AAS) being marketed as nutritional supplements, which may be considered the most 
grave of mistakes. These products extend into a wide variety of substances referred to as 
‘nutraceuticals’ which may have no drug benefits at all despite what the manufacturer 
attempts to convince the consumer. Of utmost concern however, are the potential 
implications of androgen use in the development of cancer and otherwise abnormal 
physiological changes in the body within this demographic, thereby making them a 
serious target of concern [Bryden et al., 1995; Bydder et al., 2007; Creagh et al., 1988; 
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Froehner et al., 1999; Martorana et al., 1999; Overly et al., 1984; Tentori and Graziani, 
2007; Velazquez and Alter, 2004]. 
 
AAS are classified as synthetic derivatives of T [Hartgens and Kuipers, 2004; Mottram 
and George, 2000]. The androgenic effects of these drugs influence male properties such 
as aggression, strength, hair growth and sexual regulation [Hartgens and Kuipers, 2004]. 
The anabolic action of AAS achieves protein synthesis necessary for the production of 
muscle mass, while counteracting catabolism, or the degradation of proteins and muscle 
loss. Because complete separation of androgenic action from anabolic action has proven 
unattainable to date, health concerns over the use of these products primarily stems from 
the androgenic effects. Because T is inactivated by the liver when injected or 
administered orally, AAS are also altered with the goal of withstanding liver degradation. 
This is typically achieved via structural modifications such as methylations, alkylations, 
and esterifications which slows compound metabolism [Mottram and George, 2000]. Due 
to these issues, it is essential that users of AAS understand that despite marketing as 
anabolics or dietary supplements, these compounds do possess some androgenic activity 
and therefore must be used with caution. Most times the health risks associated with AAS 
are reversible, but with continuous use may lead to irreparable damage. These risks may 
include hypertension, carcinoma, infertility, gynecomastia, tendon damage, insulin 
resistance, and undesirable psychological conditions like mania, depression, and 
aggression [Hartgens and Kuipers, 2004; Mottram and George, 2000]. Additionally, 
moral and ethical opposition to AAS exists within professional sports because of the 
lending of unfair advantages to those athletes or teams who use them. 
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In addition to the plethora of research on an androgenic role in Pca development, 
androgens have also been linked to carcinomas of the kidneys, liver, and testes. One of 
the first diagnosed cases of renal malignancy associated with steroid use was reported by 
Prat et al (1977) in a middle aged man who had competed as a professional bodybuilder 
and had used steroids for multiple years [Prat et al., 1977]. In 1995, two bodybuilders 
were diagnosed with renal carcinoma, one who had been using steroids for 20 months 
and the other for 6 years [Bryden et al., 1995], and a fourth bodybuilder was diagnosed in 
1999 who had been taking steroids for 15 years [Martorana et al., 1999]. His cancer had 
progressed with metastatic lesions having formed in the lungs. There is at least one 
documented case of a form of testicular cancer found in a competitive weightlifter who 
had been using systematic high doses of steroids for five years [Froehner et al., 1999]. 
Because of the rarity of his tumor, and the authors only knowing of three other cases of 
this kind, they state that there may be a more than causal link to androgens and cancer. 
More frequently documented however, are cases of hepatotoxicity in steroid abusers. An 
earlier report in 1984 documents hepatocellular carcinoma in a young bodybuilder who 
had consumed steroids for four years [Overly et al., 1984]. His case was of interest to 
doctors because of the lack of any prior disease or condition that may have contributed to 
the malignancy. In 1988, another bodybuilder upon entering a hospital, admitted to 
having taken steroids for at least three years [Creagh et al., 1988]. The patient 
unfortunately had a tumor, later diagnosed as a hepatocellular adenoma, which ruptured 
and hemorrhaged so badly that he lost his life. Further examination showed cardiac 
hypertrophy and testicular atrophy. Bagia et al (2000) also documented hepatic adenomas 
in a young bodybuilder [Bagia et al., 2000]. Although in this case the tumors were 
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benign, they had previously undergone internal hemorrhaging as well. In 2005, two 
bodybuilders, one having used steroids for 15 years and the other for 6 months, displayed 
hepatic adenomas [Socas et al., 2005]. The patient who had used steroids for 15 years 
also showed evidence of previous hemorrhaging within the tumor.  
 
In addition to these cases where anabolic steroids are associated with cancer 
development, hepatocellular carcinoma has also been observed in patients diagnosed with 
Fanconi’s anemia, a condition where androgen treatment is recommended when a 
suitable stem cell donor is unavailable [Velazquez and Alter, 2004]. Age does not 
discriminate in these patients, nor does the method of steroid administration (oral or 
parenteral). Finally, both liver toxicity [Kafrouni et al., 2007] and the development of 
subdural haematomas in the brain [Alaraj et al., 2005] have also been linked to anabolic 
steroid abuse in men. 
 
AAS administration has also been shown to effect blood serum levels in men. 
Specifically, sublingual 5Adiol administration has been shown to increase serum T and 
estradiol levels in men whereas oral intake does not [Brown et al., 2002; Brown and 
McKenzie, 2006]. This is of great significance since multiple studies on hormonal 
response to AAS have administered drugs orally and not observed effects due to liver 
metabolism and clearance from the bloodstream. There are studies however that have 
used oral administration methods and found increases in serum androgen levels. For 
instance, when 4-androstenedione was administered orally, small significant increases in 
serum and free T levels were observed, whereas although not significant, oral intake of 4-
androstenediol also increased T levels [Earnest et al., 2000]. Furthermore, herbal 
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supplements containing 4-androstenediol, marketed to increase serum T levels, produced 
increases in serum free T levels as well as estradiol, androstenedione, and DHT [Brown 
et al., 2001]. Broeder et al demonstrated that oral T supplementation significantly 
increased serum levels of estradiol, DHEA, and androstenedione as well as the 
participants lipid ratio risk (LDL:HDL) [Broeder et al., 2000]. 
 
Perhaps most disturbing of all were the findings of a recent web survey conducted by 
Parkinson and Evans (2006) within an anonymous group of weightlifters, bodybuilders, 
recreational and professional sports athletes [Parkinson and Evans, 2006]. From this 
study, designed to elucidate current AAS trends amongst users, they found that 26% of 
participants admitted to starting AAS use in their teens, 60% admitted to administering a 
weekly dose of greater than or equal to 1000 mg of AAS, nearly 100% use both 
parenteral and oral administration to achieve the megadoses, 45% use steroids for 6+ 
months each year, and up to 13% practice unsafe injection practices including sharing 
needles or multi-dose vials and reusing needles. Compounding these figures, nearly all 
participants admitted to experiencing three or more subjective side effects such as acne, 
insomnia, edema, mood alterations, gynecomastia, and testicular atrophy. Yet, rather than 
stopping their doping regimens, 95% of participants took additional medications to 
alleviate these symptoms. For example, to reverse endogenous T suppression and 
testicular atrophy as well as attempt to revamp natural hormone production, 40% of 
participants self-administered human chorionic gonadotropin and clomiphene. Tamoxifan 
and other antiaromatase medication usage were also documented to block symptoms of 
gynecomastia. Additional medications taken to aid in appetite suppression or fat loss 
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included growth hormone, insulin, IGF-1, thyroid medications, ephedrine, caffeine, and 
clenbuterol [Parkinson and Evans, 2006]. 
 
Taken together, in addition to the multiple side effects of AAS, the evidence surrounding 
Pca stimulation is of great concern within this demographic because it can certainly be 
prevented. Few studies have investigated the effects of over-the-counter products 
advertised as 5Adiol on either Pca development or progression. 5Adiol is an androgen 
presumed to be relatively inactive, but from some of the literature described above, it 
may be worth investigating whether marketed 5Adiol products possesses comparable 
activity to some of the other metabolically active androgens, such as T or DHT. Because 
of the easy availability of AAS products over the internet from less than reputable 
sources, the main focus of this thesis was to analyze the effects of one marketed 5Adiol 
product (Value Nutrition’s 5-Diol Powder; myvitanet.com) on the androgen-dependent 
Pca cell line, LNCaP. Whereas this product is no longer available through the company 
website, other AAS are still marketed to consumers. For all experiments using the 5Adiol 
product, it was assumed that the powder was comprised of pure 100% 5Adiol. The effects 
of this 5Adiol product were compared to those induced by T, which was purchased from 
Sigma-Aldrich Company, a well-known and reputable chemical company. In the first 
goal tested, it was hypothesized that 5Adiol and T will induce proliferation in the LNCaP 
cell line. Second, due to the role of the liver in androgen metabolism, links of androgen 
use to hepatic carcinoma, and previously unpublished data by our lab suggesting a 
mitogenic role in LNCaP proliferation from hepatic involvement [Nolan, 2002], it was 
predicated that conditioned medium from 5Adiol- and T-incubation with a hepatocellular 
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carcinoma cell line (HepG2) will stimulate a mitogenic response from LNCaP cells. It 
was also speculated that the HepG2 cells will not respond to androgen treatment. Finally, 
it was hypothesized that 5Adiol would be converted to a more metabolically active 
androgen, such as T by the LNCaP cell line. 
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MATERIALS AND METHODS 
 
 
Cell Culture 
 
Hepatocellular cancer cell line, HepG2 (HB-8065) and prostate carcinoma cell line, 
LNCaP clone FCG (CRL-1740) were purchased from the American Type Culture 
Collection (ATCC) (Rockville, MD). For MTT assays (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) only, cells were cultured in medium containing (1:1) 
DMEM:F12K supplemented with 10% fetal bovine serum (FBS), 1% non-essential 
amino acids (NEAA), and 5 x 10-5 M 2-mercaptoethanol (2-ME). Treatment medium for 
the MTT assays only was defined as described above but used 10% dextran-charcoal 
treated fetal bovine serum (DCT-FBS) in place of the 10% FBS. DCT-FBS contains 
reduced lipid levels for treatments so that the cells are cultured only in the presence of 
those lipids (androgens) supplemented back into the culture.  
 
Standard medium for all other experiments required cells to be cultured in RPMI1640 
with high glucose (2mM), supplemented with 10% FBS, 1% NEAA. Treatment medium 
for all assays other than the MTT assay was supplemented with a reduced concentration 
of 2% FBS. Cells were routinely fed 2-3 times per week and passaged either using 0.25% 
trypsin-EDTA or scraped from the culture surface at approximately 80% confluence. 
LNCaP cells were used between passages 3-9 and HepG2 between passages 3-10. All cell 
lines were maintained in humidified incubators at 37oC, 5% CO2. 
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MTT Assay 
According to Mosmann (1983), changes in cell number in response to androgen treatment 
were observed using MTT (thiazoyl blue, Sigma) with minor modifications to the 
original protocol [Mosmann, 1983]. This assay is based upon the reduction of MTT to a 
formazan crystal that can be solubilized and analyzed spectrophotometrically. Briefly, 
MTT was dissolved in 1X phosphate buffered saline (PBS) at 5 mg/mL. At the end of 
each treatment time period, MTT treatment medium (10% DCT-FBS) was removed from 
well of the 96-well assay plate and 100 μL of MTT diluted 1:10 in treatment medium was 
added to each well and incubated for 3 hours in humidified 37oC, 5% CO2 in the dark. 
100 μL of 0.1N or 0.4N HCl isopropanol (HCl-ISP) was then mixed into each well and 
shaken for 10 minutes. Wells were read using a Molecular Devices Spectramax 340 with 
a test wavelength of 570 nm and a reference wavelength of 630 nm. 
 
MTT Assay for Androgen Treatment Time Determination 
To determine androgen treatment times (0, 6, 12, 24, 48, 72, or 96 hours), LNCaP cells 
were trypsinized and plated in 96-well flat-bottomed plates at a final concentration of 
12,500 cells/mL (using a hemocytometer) in standard medium (10% FBS) and 
maintained in humidified 37oC, 5% CO2. At each respective time point, the standard 
medium was removed, treatment wells were rinsed with 1X PBS, and 200 μL of 
treatment medium (10% DCT-FBS) was added for a 24 hour lipid starvation period. 
Wells in quadruplicate were then treated with either T (Sigma) or 5-Adiol (Value 
Nutrition’s 5-Diol Powder; myvitanet.com) dissolved in 100% ethanol at final well 
concentrations of 1 nM, 10 nM, or 100 nM. The 5Adiol product was assumed to contain 
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100% 5Adiol and was weighed according to 5Adiol’s molecular weight. Control wells 
were treated with 100% ethanol. All treatment wells were assayed for increases in 
cellular proliferation compared to controls using the colorimetric MTT assay. Relative 
cell numbers were determined using a standard curve where cells/well (abscissa) was 
plotted against the absorbance readings at 570 nm (ordinate).  
 
MTT Assay for Androgen Concentration Determination 
LNCaP cells were trypsinized and plated in quadruplicate in 96-well flat-bottomed plates 
as described above to determine androgen treatment concentrations. T or 5-Adiol 
dissolved in 100% ethanol was administered after 24 hrs of lipid starvation at final well 
concentrations of 1 nM, 10 nM, or 100 nM for 24 hours. Controls were treated with 
100% ethanol. Relative cell numbers were calculated using a standard curve where 
cells/well (abscissa) was plotted against the absorbance readings at 570 nm (ordinate). 
 
DNA Content Analysis to Determine Androgen Treatment Time  
 
LNCaP and HepG2 cell lines were removed from their culture surfaces, washed with 1X 
PBS, and re-plated in 24-well assay plates using treatment medium (2% FBS) at a final 
cell concentration of 5,000 cells/mL (using a hemocytometer for cell counting) for 24 
hours in humidified 37oC, 5% CO2. T or 5Adiol dissolved in 100% ethanol was then 
added to wells in quadruplicate at final concentrations of 1 nM, 10 nM, or 100 nM for 12, 
24, or 48 hours. Ethanol volume did not exceed 1%. Control wells were treated with 
100% ethanol. At the start of each time period, tritiated thymidine (final concentration: 1 
μCi/mL; specific activity: 61 Ci/mmol; MP Biomedicals, Inc.) was also added to each 
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well and incubated in humidified 37oC, 5% CO2 for the specified length of treatment (i.e. 
1 μCi/mL tritium and 10 nM 5Adiol were added at the same time for a 12 hour treatment 
period). After medium removal, cells were washed with a solution comprised of ice cold 
10 mM sodium phosphate (Na3PO4), 150 mM sodium chloride (NaCl), pH 7.4 containing 
10mM sodium pyrophosphate (Na4P2O7) and then the solution was aspirated. 100 μL of 
1% sodium dodecyl sulfate (SDS) was added and cells were scraped from culture surface. 
Wells were then washed twice with 1 mL of ice cold water and combined with cell 
suspension. 100 μL was removed for protein determination and to the remaining volume 
0.5 mL of 50% trichloroacetic acid (TCA, MP Biomedicals, Inc.) (f.c. 10%) was added, 
vortexed, and incubated on ice for 10 minutes. DNA was collected by filtration onto 
Whatman GF/C filters. Filters were washed with 2 mL 5% TCA and placed into a 
scintillation vial with 2 mL of scintillation fluid (Scintisafe Econo1, Fisher). Samples 
were read using a Beckman Coulter LS6500 Multi-Purpose Scintillation Counter. 
Optimal culture time was chosen dependent upon when maximum increase in DNA 
content occurred.  
 
DNA Content Analysis to Determine Androgen Concentration 
Following the general protocol from the time determination section above, cells were 
cultured with 1 nM, 10 nM, or 100 nM of T or 5Adiol for 24 hours. At the start of the 
treatment period, 1 μCi/mL of tritiated thymidine was also added to the treatment 
medium (2%). After 24 hours, the DNA was collected and the labeled content was 
counted. Optimal androgen concentration was chosen pending which treatment promoted 
the maximal increase in DNA content during the treatment period. 
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Western Blot for Proliferating Cell Nuclear Antigen (PCNA) 
Cells were isolated from culture surface and washed with 1X PBS to remove exogenous 
proteins, and lysed via freezing at -20 oC. Sample volumes for gel loading were 
determined using the Coomassie Plus – The Better Bradford Assay Kit (Pierce) so that 
samples were normalized to total protein. This assay relies upon the binding of coomassie 
dye to proteins which causes a shift in absorption from 465 nm to 595 nm. Total protein 
concentration of the samples was estimated by reference to the absorbencies obtained 
using a standard curve for bovine serum albumin. 5X Laemmli tracking dye was added to 
all samples and diluted to a final concentration of 1X in PBS. Samples were boiled for 3-
5 minutes at 100oC and loaded onto either a 10% polyacrylamide iGel or NuBlu gel (Life 
Therapeutics) and run at 40 mA for approximately 30-60 minutes in tris-glycine buffer 
(25 mM tris, 192 mM glycine, 1% SDS). Gel was blotted onto an Immobilon-P transfer 
membrane (PVDF) at 200 mA for 30 minutes. Membrane was blocked in 5% blocking 
buffer (dehydrated milk in 1X PBS) at least 1 hour, incubated overnight at 4oC with 
either mouse monoclonal anti-PCNA (2.5 μg/mL) or rabbit polyclonal anti-PCNA 
(1:1,000) (Calbiochem). The membrane was subsequently washed twice with 1X tris 
buffered saline (TBS), pH 7.4 followed by two washes with 1X TBS, 0.1% Tween 20, pH 
7.4, each lasting at least 15 minutes. Washing was followed by incubation with 
appropriate secondary [goat anti-mouse IgG alkaline phosphatase conjugate (1:5,000) or 
goat anti-rabbit IgG alkaline phosphatase conjugate (1:10,000)] at 4oC for at least 1 hour. 
Pierce 1-Step NBT/BCIP solution was used for band development. Blots were analyzed 
by densitometry using Scion Image, a free image analysis program offered through Scion 
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Corporation (Frederick, MD; http://www.scioncorp.com/) in collaboration with the NIH. 
LNCaP blots were repeated in triplicate; HepG2 in duplicate.  
 
Organic Extractions 
According to the method supplied by JoAnn Whitefleet-Smith [Whitefleet-Smith, 1984], 
cell culture medium samples from androgen treatments were mixed in a one phase 
solution of 2:1:0.8 methanol (MeOH):chloroform (CHCl3):water (H2O) (v:v) and mixed 
thoroughly. Phase separation was initiated by the addition of 1 volume of CHCl3 and 0.2 
volumes of H2O. The entire solution was mixed well and the organic layer was collected 
and evaporated to dryness under nitrogen using an N-EVAP 111 nitrogen evaporation 
setup with an OA-SYS heating system, set to 30oC. 
 
Reverse-Phase High Pressure Liquid Chromatography (RP-HPLC) 
RP-HPLC was performed according to a documented method for testosterone analysis 
[Navajas et al., 1995]. Briefly, a Hewlett-Packard HP 1100 series liquid chromatograph 
was used to analyze 20 μL sample injections at either 240 or 254 nm (wavelength 
specified within text) on a C18 250 X 4.6 mm reversed-phase analytical column. A flow 
rate of 1.2 mL/min was maintained in a mobile phase comprised of 1 mM phosphoric 
acid and acetonitrile. The starting acetonitrile concentration of 15% was increased to 30% 
in 10 minutes, 35% in 16.5 minutes, and sustained at 35% until 28 minutes where initial 
conditions were reinstated.  
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Statistical Analysis 
Sigmaplot v.9 software was used to perform statistical tests. Dependent upon the 
experimental design, a one-way ANOVA, two-way ANOVA, or randomized blocked 
two-way ANOVA was used (chosen test is stated within text), considering p<0.05 to be 
significant. If significant differences were found, the Holm-Sidak post-hoc analysis was 
performed. 
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RESULTS 
 
Time Course Investigation and Optimal Androgen Treatment Concentration Study 
of LNCaP Cells 
 
Initial studies to determine the optimal length of LNCaP treatment with either 5Adiol or 
T were explored using the MTT assay. Since the MTT assay is normalized by cell 
number, the most important factor necessary for optimization of the assay is cell 
adherence to the culture substrata. The earliest MTT trials were inconclusive due to inter-
experimental variability. Macroscopic observation suggested the variability was a result 
of cell loss during solvent addition and removal. Poly-lysine culture surface treatment or 
culture on Corning® Cellbind® plates (Figure 5) were used to enhance cell attachment.   
 
Although these changes appeared to reduce experimental variability (Figure 5), cells 
continued to detach during solvent changes. However, the assay did appear to work more 
efficiently at lower cell densities (20-40,000 cells/well), perhaps due to a reduced cell-
cell and an increased cell-substrate attachment at lower densities (data not shown). Thus, 
successive assays were carried out at lower cell densities. 
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(B). (A). 
Figure 5. Absorbance of MTT crystals at 570 nm from LNCaP samples. 
The MTT standard curve was derived from cells plated on either Corning® Cellbind® plates (A) or poly-
lysine coated plates (B), respectively. Standard curves ranged from 10,000-100,000 cells/well. Data shown 
are mean ± standard error of the mean.  
 
 
In one time course study of LNCaP cells treated with a single dosage of androgen over a 
range of concentrations, the data supported an optimal treatment time period between 0-
24 hours (Figure 6). At 48 hours of treatment, there was a significant drop in viable cell 
number (p<0.05; two-way ANOVA) which continued to be evident at all subsequent time 
points. Perhaps androgen treatment has a negative impact on cellular proliferation or 
viability after two days in culture. Because cells continued to detach from the culture 
wells, further interpretation of these data were speculative at best. 
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Androgen Treatment of LNCaP During Four Days in Culture
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Figure 6. LNCaP proliferation over four days in culture in response to either 5Adiol or T treatment. 
Cells were plated at a density of 2,500 cells/well on poly-lysine coated plates. MTT crystals were dissolved 
with HCl-ISP. Control data are shown for 24 hours, but absent for all other time points. Groups are 
averaged from triplicate wells from each treatment within this single experiment. 
 
 
Centrifugation of the LNCaP cells prior to solvent addition/removal, use of alternative 
culture medium, plating cells onto a larger culture surface area, and increased time 
between plating and treatment did not significantly improve the situation. Therefore, an 
alternative assay system was used in subsequent studies. The use of tritiated thymidine to 
measure DNA replication was used as the second measure of cellular proliferation 
because collected data can be normalized to either cell number or total protein 
concentration within samples. 
 
Additionally, because cells plated in DCT-FBS did not appear mitotically robust, an 
investigation was performed to determine whether the use of 5% FBS in culture medium 
could improve cell adhesion over 24 hours. Indeed, higher cell counts were obtained in 
medium containing 5% FBS (data not shown) than in 10% DCT-FBS medium. Therefore, 
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2% FBS was investigated to minimize the amount of lipids in the culture medium without 
sacrificing cell viability (Figure 7). Higher cell densities (100-200,000 cells/well) were 
plated in the attempt to mitigate subsequent cell loss, and a single dose of 10 nM 5Adiol 
or T was administered for 24 hours. Differences due to treatment were more readily 
evident in 2% FBS compared to 10% DCT-FBS (Figure 7). Only two of four trials 
showed a similar trend of responsiveness to steroid treatment compared to a vehicle 
control [ethanol (EtOH) only] for the 2% FBS group. In the other two trials there was 
either a decrease or no change in cell number as a result of treatment. The 10% DCT-FBS 
group responses to treatment varied with every trial. It is likely that cell attachment 
continued to contribute to inter-assay variability and confound interpretation of results. 
However, for whatever advantage it conferred to cellular adhesion, culture medium 
containing 2% FBS was used throughout the remaining assays since DCT-FBS contains 
fewer lipids, which may be necessary for cell attachment and proliferation.  
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Figure 7. LNCaP proliferation in response to treatment with 10 nM 5Adiol or T. 
Cells were plated in culture medium containing either 2% FBS (100,000 cells/well) or 10% DCT-FBS 
(200,000 cells/well). The experiment was repeated four times. This figure is representative of the data trend 
that was repeatable in two of the four trials. Groups are expressed as the average of each treatment from 
triplicate well. Standard error is not shown because this experiment was performed once.  
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A time course study of LNCaP cells using tritiated thymidine at 12, 24, and 48 hours 
showed an optimal time point of 24 hours with an apparent increase in proliferation at all 
doses compared to vehicle control (Figure 8). This was in keeping with initial 
observations using the MTT assay (Figure 6). Additionally, as seen in the MTT data, a 
decrease in viable cell number was observed at 48 hours. Although there was significant 
variability, the data from this experiment suggested that a concentration of 10 nM be used 
in further trials since 10 nM 5Adiol supported the greatest increase in cell number at each 
time point when compared to 1 nM or 100 nM 5Adiol. 
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Figure 8. LNCaP proliferative response to a single androgen dosage using tritiated thymidine. 
A single dose treatment with either 1, 10, or 100 nM 5Adiol or T was administered for 12, 24, or 48 hours 
in culture. Cells were plated at a density of 100,000 cells/well in culture medium containing 2% FBS. 
Groups are expressed as the average from triplicate wells. Standard error is not shown because this 
experiment was performed once.  
 
In a final attempt to mitigate the problem of cell detachment, BD Biocoat™ fibronectin-
coated plates were used to enhance cell adhesion (Figure 9).    
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LNCaP Response to 24 Hour Androgen Treatment 
When Plated on Fibronectin-Coated Plates
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Figure 9. LNCaP proliferative response to 24 hours of androgen treatment. 
Cells were plated at a density of 100,000 cells/well in culture medium containing 2% FBS on BD 
Biocoat™ plates. Data shown are mean ± standard error of the mean. 
 
 
When observed macroscopically on the fibronectin-coated plates cell attachment seemed 
vastly improved compared to prior methods. However, the differences among all 
treatments were indistinguishable from the control (one-way ANOVA, p = 0.474; p<0.05 
considered significant). Since changes in focal attachment using fibronectin have been 
shown to have an effect on signal transduction pathways, this approach was not pursued. 
Thus, all future trials were conducted using 10 nM androgen over a 24 hour time period 
on standard-treated tissue culture plastic. 
 
 
LNCaP and HepG2 Expression of PCNA in Response to Androgen Treatment  
 
Proliferating cell nuclear antigen (PCNA) is a 35 kDa auxiliary protein of DNA 
polymerase δ [Bravo et al., 1987]. Ιts nuclear concentration directly correlates with DNA 
replication, thereby making it an optimal protein for proliferative studies. As a secondary 
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validation to the tritiated thymidine assay, the expression of PCNA in response to 24 
hours of 10 nM androgen treatment in the LNCaP and HepG2 cell lines was explored 
(Figures 10 & 11). Furthermore, the proliferative response of LNCaP cells after 24 hours 
of culture with conditioned medium from HepG2 cells treated with either 10 nM of 
5Adiol or T for 24 hours was also investigated.  
 
Immunoblot analysis of LNCaP cell samples revealed a positive proliferative response to 
androgen treatment compared to vehicle only (Figures 10A-D), although one blot did not 
show as strong of a response to 5Adiol (Figure 10C). While both androgens were able to 
stimulate proliferation, T consistently proved to have a greater effect than 5Adiol. This 
finding contradicts those found by Mizokami et al where picomolar levels of 5Adiol were 
found to induce greater proliferative effects than testosterone [Mizokami et al., 2004]. 
This might be explained by later experiments using reverse-phase high performance 
liquid chromatography (RP-HPLC), which suggest that this 5Adiol product by Value 
Nutrition may not actually contain 5Adiol.  
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Figure 10. Western blot of PCNA expression in LNCaP cells after 24 hours of 10 nM androgen 
treatment. 
(A-C) First, second, and third PCNA blots from LNCaP samples, respectively. Lanes are as follows: 1 – 
Marker, 2 – LNCaP EtOH control, 3 – LNCaP 10 nM 5Adiol, 4 – LNCaP 10 nM T, 5 – LNCaP with 
HepG2 EtOH control medium, 6 – LNCaP with HepG2 10 nM 5Adiol medium, 7 – LNCaP  with HepG2 
10 nM T medium. Sample loading was normalized to total protein (μg/mL). (D) Graphical representation 
of the compiled band intensities from each blot as analyzed by densitometry. Groups are mean ± standard 
error of the mean; * indicates statistical difference between groups. 
 
Graphical representation of the LNCaP data is shown in Figure 10D. The band intensity 
from each blot was measured using Scion Image. To compare relative differences 
between groups, the values from each blot were averaged together and analyzed using a 
randomized blocked two-way ANOVA. Although an androgen response is seen by 
observing the blots subjectively, significant differences were not found between androgen 
treatment of LNCaP cells compared to the control (p = 0.106, with p<0.05 considered 
significant). However, the general trend from the blots supports the tritiated thymidine 
assay conclusion that LNCaP cells are androgen responsive to both 5Adiol and T 
compared to vehicle after 24 hours of treatment. 
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To analyze the effect of hepatic androgen metabolism on Pca progression, HepG2 cells 
were treated with EtOH, 5Adiol, or T for 24 hours. The conditioned medium was then 
harvested, spun down to pellet any cell debris, and the supernatant was added to a flask of 
LNCaP cells and allowed to incubate for 24 hours. As shown in Figures 10A-C; lanes 5-
7, two of the three blots showed a stimulated growth response of LNCaP cells to HepG2 
conditioned media from 5Adiol and T treatments (Figures 10B&C), whereas the third 
blot showed an inhibition of their mitogenic capability (Figure 10A). Similar to what was 
found with the androgen treatment of LNCaP cells, the HepG2 conditioned medium from 
treatment with T also induced a greater level of proliferation in the LNCaP cells 
compared to HepG2 conditioned medium from 5Adiol treatment. Statistical analysis by 
the randomized blocked two-way ANOVA detected significant differences between the 
treatment groups, but not between treatments and control (p = 0.026, with p<0.05 
considered significant). These data suggest that hepatic metabolism of androgens may 
play a role in the acceleration of prostate cancer development and maintenance. 
 
To determine whether the HepG2 cells respond to androgen treatment as a mitogenic 
stimulus, the expression of PCNA was explored (Figures 11A-B). Interestingly, the 
HepG2 cells were responsive to 5Adiol, although the response to T was conflicting. 
Statistical analysis by a randomized blocked two-way ANOVA did not find significant 
differences between the androgen treatment groups and/or the ethanol control (p = 0.515, 
where p<0.05 is considered significant).  
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Figure 11. Western blot of PCNA expression in HepG2 cells after 24 hours of 10 nM androgen 
treatment. 
(A) First and (B) second PCNA blot of HepG2 samples. Lanes are as follows: 1 – Marker, 2 –EtOH 
control, 3 –10 nM 5Adiol, 4 – 10 nM T. Sample loading was normalized to total protein (μg/mL). (C) 
Graphical representation of compiled band intensities from both PCNA blots after densitometry analysis. 
Data shown are mean ± standard error of the mean. 
 
 
Androgen Detection by RP-HPLC in LNCaP Medium after Treatment  
 
Initial investigations into androgen conversion by LNCaP cells using RP-HPLC were not 
able to reveal any significant peaks in the androgen stocks at concentrations in the nM or 
low μM range (data not shown) at 240 nm. Using a Thermo Genesys 10uv 
spectrophotometer, the minimum detectable concentrations at 240 nm were 1 mM for 
5Adiol (0.652 AU) and 100 μM for T (0.757 AU), so concentrated stocks were made. 
Furthermore, to optimize the sample analyses, the solvent conditions of the column were 
changed from water to phosphoric acid and the injection volume was adjusted from 10 to 
20 μL. After these adjustments were made, a baseline from MeOH was collected (Figure 
12A) and a retention time for T at 22 minutes at 240 nm was successfully obtained 
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(Figure 12B) despite futile attempts to detect a peak for 5Adiol even at a 1 mM 
concentration (Figure 12C). 
 
Figure 12A. Methanol baseline profile at 240 nm. 
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Figure 12B. T profile at 240 nm. 
 
 
Figure 12C. 5Adiol profile at 240 nm. 
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Because it was unknown whether a different λmax was the cause of undetectable peaks 
from the 5Adiol stock, the wavelength was increased from 240 nm to 254 nm and both T 
& 5Adiol were reanalyzed (Figures 12D & 12E, respectively). Significant peaks for 
5Adiol were not detected, allowing for the conclusion that wavelength was not an issue. 
Furthermore, the altered wavelength did not have a diminishing effect on the absorbance 
of T, thus remaining samples were tested at 254 nm in the attempt to detect any 5Adiol 
peaks in later analyses.  
 
An alternative 5Adiol supplement (AST Science Performance Nutrition) was also tested 
at 254 nm (Figure 12F) to elucidate if there were any detectable components in another 
5Adiol product. Despite the detection of one peak at 9.8 minutes, it was of an 
insignificant amount considering the estimated stock concentration was 100 mM. 
Questions were raised as to whether the 5Adiol product used for cell treatments was a 
true androgenic compound or a false marketing campaign by the manufacturer despite the 
proliferative response it seemed to elicit.  
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Figure 12D. T profile at 254 nm. 
 
 
Figure 12E. 5Adiol profile at 254 nm. 
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Figure 12F. Alternative 5Adiol product profile at 254 nm. 
 
Because the cell medium samples from androgen treatments would need to be organically 
extracted to concentrate the hydrophobic elements (i.e. steroids) in the medium, the 
extraction efficiency was determined by using the stock solution of 1 mM T at 254 nm 
(Figures 13A&B).  
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Figure 13A. Methanol baseline after organic extraction, measured at 254 nm. 
 
 
Figure 13B. 1 mM T profile after organic extraction, measured at 254 nm. 
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Since the efficiency was calculated at 83.5% (no extraction: area = 11704; post-
extraction: area = 9777.9), 2% FBS medium controls were extracted and analyzed 
(Figures 14A-E).  
 
 
Figure 14A. Methanol baseline after extraction, measured at 254 nm. 
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Figure 14B. 2% FBS medium control after extraction, measured at 254 nm. 
 
 
Figure 14C. 2% FBS + 10 nM 5Adiol medium control after extraction, measured at 254 nm. 
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Figure 14D. 2% FBS + 10 nM T medium control after extraction, measured at 254 nm. 
 
 
Figure 14E. 2% FBS + 10 nM 5Adiol and T medium control after extraction, measured at 254 nm. 
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Examination of the 2% FBS medium controls concentrated in 50 μL MeOH showed 
multiple peaks. However, the chromatogram profiles of each control were extremely 
similar. Although the peak heights did vary between controls, and retention times may or 
may not have been assigned by the HPLC dependent upon the detection threshold, the 
peak profiles were consistent in each sample. Two peaks in particular, eluted around 11.5 
minutes, were consistent in both time and peak area throughout the analysis. These were 
initially considered to be phenol red from the medium, however, they’re presence in a 
DMSO sample (data not shown) contradicted this hypothesis since DMSO contains no 
phenol red. Thus, these compounds are unknown contaminants. Overall, these combined 
data revealed the possibility that even concentrating the androgens in a smaller volume 
may not yield detectable androgen peaks.   
 
Before moving on with cell treatment medium analysis, sample filtering was ruled out as 
a possible reason for undetectable 5Adiol peaks due to the globular proteins in FBS (data 
not shown). Prior to analysis on the column, LNCaP medium samples were extracted, 
evaporated under nitrogen and concentrated in 80 μL of MeOH (Figures 15A-E). 
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Figure 15A. Methanol baseline after extraction, measured at 254 nm. 
 
 
Figure 15B. LNCaP no treatment control measured at 254 nm. 
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Figure 15C. LNCaP EtOH control measured at 254 nm. 
 
 
Figure 15D. LNCaP sample treated with 10 nM 5Adiol measured at 254 nm. 
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Figure 15E. LNCaP sample treated with 10 nM T measured at 254 nm. 
 
 
Although peaks were seen in each sample, none appeared to be significant among the 
various treatments because the profiles were very consistent, mimicking what had been 
seen in the 2% FBS medium controls. Again, the one peak of a significant concentration 
was at 11 minutes, but its significance is unknown since it consistently appeared in each 
sample and was observed in a DMSO sample, as mentioned previously. Taken together, it 
appeared as though the detection capability of the HPLC spectrophotometer was not 
sufficient for the analysis of these samples or alternatively, that there are no androgens 
present in the 5Adiol product. 
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Androgen Detection by RP-HPLC in LNCaP Medium after HepG2 Conditioned 
Medium Treatment 
 
LNCaP medium samples from culture with conditioned medium from HepG2 androgen 
treatments were also analyzed (Figures 16A-D) at 254 nm. These samples were extracted, 
evaporated under nitrogen and concentrated in 80 μL of MeOH prior to analysis on the 
column. 
 
 
Figure 16A. LNCaP sample cultured with HepG2 no treatment control conditioned medium. 
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Figure 16B. LNCaP sample cultured with HepG2 EtOH control conditioned medium. 
 
 Error!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16C. LNCaP sample cultured with HepG2 conditioned medium from 10 nM 5Adiol 
treatment. 
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Figure 16D. LNCaP sample cultured with HepG2 conditioned medium from 10 nM T treatment. 
 
 
Reiterating what had been seen with the LNCaP medium samples, detected peaks were 
equivalent between all samples despite any observable changes in peak heights. These 
findings supported the conclusion that the detection system of the HPLC was not 
sensitive enough for the analysis of this 5Adiol product. 
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DISCUSSION 
 
As AAS become more popular in the world of competitive sports, the ever-increasing 
availability of these products quickly outpaces the resources of government agencies 
responsible for their regulatory control. With an almost nonexistent guarantee of quality 
for such products, multiple links of their use with cancer development, and contamination 
with regulated substances or mislabeled components, the use of these substances is a 
growing cause of concern [Bagia et al., 2000; Bryden et al., 1995; Bydder et al., 2007; 
Catlin et al., 2000; Delbeke et al., 2002; Froehner et al., 1999; Hartgens and Kuipers, 
2004].  
 
The major aim of this study was to investigate the effects of a 5Adiol product (Value 
Nutrition 5-Diol Powder) marketed over the internet, on the androgen-dependent prostate 
cancer cell line, LNCaP. Intraprostatic androgen conversion has been proposed to play a 
role in prostate cancer progression to androgen-independent growth, so this aim was 
important in assessing the risk of this and similar products [Nishiyama et al., 2007]. 
Treatment concentration range (1-100 nM) was chosen based upon the known 5.2 nM 
physiological level in the body [Mizokami et al., 2004]. Although the tested androgen 
range in this effort may not accurately mimic what is found in men using this substance 
for anabolic purposes, it would be uniquely difficult to do so considering the wide range 
of concentrations used by these individuals [Parkinson and Evans, 2006]. An additional 
objective of this study was to evaluate the effects of this product on a liver cell line 
(HepG2) since the liver plays a role in androgen metabolism. Because liver metabolism 
also affects serum hormonal levels, which ultimately affect other organs in the body such 
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as the prostate, the medium from HepG2 treatment with 5Adiol was also used to 
elucidate any effects of the hepatic metabolism of this product on LNCaP cells. Since the 
5Adiol was purchased from a non-reputable source over the internet, the effects of this 
product were compared to those induced by testosterone, which was purchased from the 
chemical company, Sigma-Aldrich.  
 
The major finding of this study was that LNCaP cells were stimulated to undergo mitosis 
in a dose- and time-dependent manner in response to treatments with either 5Adiol or 
testosterone. A dose-dependent response of LNCaP cells to dihydrotestosterone was 
demonstrated by Horoszewicz et al in 1983 [Horoszewicz et al., 1983] as well as by 
Mizokami et al in 2004, where LNCaP cells were treated with testosterone, 
dihydrotestosterone, dehydroepiandrosterone, and 4-androstenedione over a range of 
concentrations for four days [Mizokami et al., 2004]. Importantly, they observed a 
mitogenic response where cell proliferation increased 20% with 100 pM 5Adiol treatment 
when compared to cells treated with 100 pM of testosterone or dihydrotestosterone 
[Mizokami et al., 2004]. At a 10 nM dose after 4 days of treatment, the proliferative trend 
was 5Adiol>testosterone>dihydrotestosterone, although the authors didn’t include a 
statistical analysis of the observed difference.  
 
The data presented here suggest that treating cells with either the tested 5Adiol product or 
testosterone resulted in an increased rate of proliferation relative to untreated controls. 
Despite the case of several different assays and multiple repetitions, both inter-and intra-
experimental variability prevented robust statistical analysis of the data. However, the 
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trends observed are consistent with those of Mizokami et al even though their studies 
were carried out at very different doses. How the addition of picomolar quantities of 
substances, which are present at nanomolar levels in the normal physiologic state, would 
have an effect on cells is unclear. However, the demonstration that testosterone 
precursors even at significantly reduced levels may be mitogenic is alarming. 
 
Most of the variability in this work appeared to be related to LNCaP adhesion to the 
culture substrata, which caused great variability in the data due to the large loss of viable 
cells during solvent changes. The LNCaP cell line is characterized as a loosely adherent 
culture due to a reduced expression of the α6β4 integrin [Bonaccorsi et al., 2000], focal 
adhesion kinase [Slack et al., 2001], insulin growth factor (IGF) receptor [Reiss et al., 
2001], and tyrosine phosphatase (an immunoglobulin adhesion molecule) [Hellberg et al., 
2002], which all play critical roles in cellular adhesion and motility. Culture surface 
modifications less likely to cause significant biological changes within the cells were 
attempted, which included net charge through the use of poly-lysine, more oxygen groups 
using a Corning® Cellbind® product which stabilizes the surface for improved 
attachment, centrifugation to force the cells to the dish during solvent changes, and 
alterations in plating density or surface area. However, because these treatments did not 
appear to effectively improve the situation, the use of a fibronectin-coated surface was 
examined. Despite the drastically improved attachment to the culture wells, no significant 
differences were found, and so this avenue wasn’t investigated further for two reasons: (i) 
few groups that research androgenic effects in prostate cancer use surface modifications, 
and (ii) extracellular matrix (ECM) proteins such as fibronectin are known players in 
 59
signal transduction pathways that affect biological processes involved in cellular division. 
Where this study was dependent upon cell proliferation as a means for determining 
treatment response to androgens, an additional mitogenic variable was not desirable.  
 
Although the majority of research groups involved in androgen studies do not to utilize 
surface modifications to improve adhesion, some research has been completed using 
collagen and other ECM proteins to improve attachment and observe effects mediated on 
the LNCaP phenotype [Arnold et al., 2005; Fong et al., 1992; Guo et al., 1994]. Whereas 
the proliferation of LNCaP cells plated on ECM was found to occur in a time- and dose-
dependent manner following treatment with dehydroepiandrosterone, testosterone, 
dihydrotestosterone, or estradiol [Arnold et al., 2005], previous work [Fong et al., 1992; 
Guo et al., 1994] observed that LNCaP proliferation was either attenuated or not affected 
by ECM modification to the culture environment when compared to growth on plastic or 
collagen. Fong and colleagues logically concluded that the environment in which the 
LNCaP cells are cultured determines their cellular response, differentiated function, and 
morphological response to androgens. Where the LNCaP cell line was derived from a 
metastatic lesion of Pca [Horoszewicz et al., 1983], the reduced attachment dependence 
of these cells would allow them to be transported via the lymphatic or circulatory systems 
to metastatic sites. This lack of attachment dependence is, in fact, a hallmark of 
transformation and related to metastatic potential. Thus, modifications to the culture 
environment aimed at improving adhesion may in fact alter the native phenotype and/or 
genotype of the cells, making firm conclusions or comparisons theoretical at best. 
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As a solution to the attachment issue, 2% FBS was added to the medium rather than use 
10% DCT-FBS. Although most groups studying androgen treatment on prostate cancer 
use DCT-FBS [Arnold et al., 2005; Aspinall et al., 2004; Chen et al., 2004; Fong et al., 
1992; Gregory et al., 2001; Guo et al., 1994; Horoszewicz et al., 1983; Lee et al., 1995; 
Miyamoto et al., 1998; Umekita et al., 1996], it is unclear whether these groups have 
observed the same issues encountered in this study, or whether they acknowledge the 
issue of LNCaP adherence. For comparative reasons between this study and others, as 
well as biological rationale (i.e. cells are only treated with the androgens supplemented in 
the medium), dextran-charcoal treated FBS would have been preferred. However, it is 
unclear whether the charcoal treatment of DCT-FBS also stripped the culture of 
necessary factors for both adhesion and cell division, thereby preventing the cells from 
completing either native function. Furthermore, it cannot be ruled out whether passage 
number or alternative culture conditions used in this study may have selected for a certain 
phenotype/genotype or initiated cellular differentiation or other modifications which 
amplified the non-adherent characteristics of this cell line. Despite these arguments 
however, 2% FBS was used for whatever advantages it may have conveyed to the cells.  
 
Also giving pause for speculation is the cytotoxicity observed in both MTT and tritiated 
thymidine uptake assays at 48 hours and beyond. It is possible that because medium 
changes were not performed during the single dosage treatments, cells began to apoptose 
due to a lack of nutrients or a change in the culture pH. It may also be possible that these 
androgens were metabolized to a cytotoxic product in the LNCaP cell line. Speculations 
aside, other investigators have observed cytotoxic effects or growth arrest in LNCaP cells 
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due to higher nanomolar and micromolar level treatments using dihydrotestosterone 
[Horoszewicz et al., 1983; Lee et al., 1995]. In particular, Horoszewicz et al observed 
greater cytotoxicity when basal medium with 5% FBS was supplemented with 
dihydrotestosterone compared with basal medium plus 5% DCT-FBS and 
dihydrotestosterone. This seems logical if dihydrotestosterone can independently induce 
cytotoxic effects, whereas such effects would be compounded by normal serum, which 
already contains steroids. It may be possible that a similar phenomenon occurred with the 
5Adiol and testosterone treatment in this study, where length of treatment was somehow 
toxic for cell viability.  
 
Hepatic metabolism of the tested androgens may be an arguable factor in prostate cancer 
progression, suggested by the significantly increased PCNA expression in LNCaP cells 
when cultured with HepG2 androgen-conditioned medium. To the best of our knowledge, 
this is one of the first observations into the mitogenic effects of androgenic liver 
metabolism on prostate cancer. The liver is known to express key enzymes in androgen 
metabolism, namely the 5α-reductases and 17β-hydroxysteroid dehydrogenases (17HSD) 
[Andersson et al., 1995; Soronen et al., 2004; Vihko et al., 2006]. Whereas the 17HSD 
are known to inactivate active estrogens and androgens, such as testosterone to 
androstenedione, the reductases catalyze the opposite reaction, where steroids are reduced 
to a more active metabolite. The expression of both types of enzymes permits the liver to 
have a regulatory role in both local and systemic steroid metabolism as well as serum 
hormone levels. It can be postulated that in malignant transformation, alterations in these 
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enzyme’s expression patterns would have drastic effects upon the progression of a 
malignancy that responds to an androgenic stimuli. 
 
Although solid conclusions cannot be made regarding the response of the HepG2 cell line 
to androgen treatment, due to the small sample size and observed variability in the 
response to testosterone, it appears as though androgen treatment with 5Adiol may 
stimulate the proliferation of this cell line. However, this data is contradicted by one 
attempt to study HepG2 proliferation by tritiated thymidine uptake, which did not show 
any significant differences between androgen treatments (data not shown). It is likely that 
more repetitions would clarify this response. Despite the hypothesis that proliferation 
would not be stimulated in response to androgen treatment, the response of the HepG2 
cells to 5Adiol was unknown at the start of this study. This was primarily due to a limited 
number of investigations having been previously conducted that evaluated the role of 
androgens, or the expression of the androgen receptor, in liver cancer in vitro. Lim et al 
determined in 1997 that 25 nM dihydrotestosterone induced proliferation of HepG2 cells 
[Lim et al., 1997]. However, a very recent study in 2007 by Jie et al demonstrated that 
androgen receptor mRNA levels are expressed at lower concentrations in HepG2 cells 
compared to other hepatocellular carcinoma cell lines, and furthermore, that HepG2 
treatment with 100 nM dihydrotestosterone elicits only a modest increase in proliferation 
[Jie et al., 2007]. These results may be attributed to the fact that translational expression 
of the androgen receptor was not investigated, and the modest increase in proliferation 
may be due to cytotoxic effects of higher concentrations of dihydrotestosterone, which 
has been seen with prostate cancer cell lines [Horoszewicz et al., 1983; Lee et al., 1995]. 
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If the androgen receptor is only weakly translated in the HepG2 cell line, it is possible 
that the effects observed in our study were related to androgen regulation of the insulin-
like growth factor-1 receptor (IGFR). This protein was shown to be upregulated in 
prostate cancer by androgen treatment [Pandini et al., 2005], and is a known vital 
component of growth, apoptotic resistance, and invasiveness in malignant growths. 
Pandini et al also showed that the androgen-induced upregulation is mediated through 
kinase activation of the androgen receptor, which is an alternative pathway to ligand 
binding activation for this receptor. 
 
The hypothesis regarding 5Adiol conversion to testosterone was unable to be tested due 
to the limited detection capability of the reverse-phase high performance liquid 
chromatography (RP-HPLC) spectrophotometer. The concentrations tested were likely 
too small to be observed, thus making conclusions impossible. It is interesting to note that 
attempts to concentrate the stock 2% FBS medium control containing 10 nM testosterone 
did not result in discernable peaks in the chromatogram. Although these efforts changed 
the initial concentration of 10 nM to 334 nM, the final concentration was still 10-fold 
lower than the calculated maximum detection limit of 5 μM. Sample filtering was also 
ruled out as a possible means of androgen entrapment prior to column analysis. 
Concentration of urine samples for analysis by RP-HPLC was sufficient for the detection 
of testosterone at a lower limit of 69 nM [Navajas et al., 1995]. Because of this study by 
Navajas et al, it was proposed that 10 nM of androgen treatment in our study would have 
been detectable on the HPLC system used here, but this was obviously not successful. 
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In contrast to the relative ease of testosterone detection, the inability to detect significant 
peaks for multiple 5Adiol products even at high concentrations (1 mM and 100 mM) is 
very disconcerting. These levels were well above what should have been the detection 
limits when calculated using the product information (250mg of 5Adiol twice daily, 
which approximates to a serum level of 157 μM at any given time, assuming a blood 
volume of 5.5 L). The prior knowledge that 5Adiol was undetectable at high 
concentrations led to the assumption that it would not be detected in the medium controls 
or LNCaP treatment samples since those were supplemented with a concentration 10,000-
fold lower than the 1 mM stock. However, the retention time of 5Adiol was still deduced 
in order to propose where the compound theoretically would’ve come off the column 
(Figure 17). Based upon the compound structure and polarity, 5Adiol would be expected 
to elute prior to testosterone using the same RP-HPLC system. This is theorized because 
of its slightly more polar structure which contains two hydroxyl groups compared to the 
structure of testosterone which contains one hydroxyl and one ketone group (Figure 3). 
However, because these molecules are so similar in structure, and extrapolating from 
relative retention times in another solvent system, the theoretical elution of 5Adiol would 
likely be expected within a few minutes of testosterone (3-5 minutes maximum).   
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 5Adiol 
Testosterone 
Figure 17. Theoretical elution peak of 5Adiol with respect to testosterone. 
 
Despite not being able to detect significant peaks that may have been attributed to any 
one particular compound from the 5Adiol supplement, it is interesting to speculate about 
the mitogenic stimulus of LNCaP cells due to treatment with this product. This issue is of 
great concern because a compound(s) within the product that maximally absorbed at  
254 nm was detected (through the use of an alternative spectrophotometer). It is 
impossible to propose exactly what compound or combination thereof might have been 
the cause of action without further analysis. However, possibilities may include human 
growth hormone or an alternative growth factor such as IGF, epidermal growth factor 
(EGF), hepatocyte growth factor (HGF), fibroblast growth factor (FGF), or a protein such 
as insulin, lectin, or other plant hormone. Furthermore, it is entirely possible that 5Adiol 
or other androgens are components of Value Nutrition’s 5Adiol product and that they are 
simply present at very low quantities within the powder. However, to determine this, the 
product needs to be analyzed by a more sensitive technique with standard controls for 
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comparison. Analysis of picomolar levels of androgens has been successful using mass 
spectroscopy, liquid chromatography, gas chromatography, or a combination thereof, so 
perhaps these are viable alternatives  [Higashi et al., 2006; Mitamura et al., 2002; 
Nishiyama et al., 2007; Titus et al., 2005]. Additionally, Mizokami et al has suggested 
that 5Adiol is more effective than testosterone even at doses in the picomolar range 
[Mizokami et al., 2004]. 
 
Future studies from this investigation are limitless. First and foremost, the mitogenic 
effects of 5Adiol and testosterone should be repeated to confirm the results reported 
herein. However, one critical necessity is a 5Adiol standard. Although 5Adiol itself is not 
sold through any of the chemical companies we have contacted (VWR, Fisher, JT 
Baker/Mallinckrodt, Pfizer, FMC Corp, Genentech, Eastman chemical Company, Dow 
Chemical, Bristol-Myers Squibb, BASF, DuPont, and J&J), ethynyl androstenediol is 
available through Sigma Aldrich. It would be difficult to synthesize 5Adiol from this 
product, but it is possible. More likely however, is the prospect of using 
dehydroepiandrosterone to manufacture the compound, which was exactly what was done 
by Higashi et al to obtain a 5Adiol standard [Higashi et al., 2006].  
 
Future studies should include determining the effects of these androgens on prostate 
specific antigen (PSA) expression in prostate cancer, which is the current primary 
diagnostic marker for this malignancy. The potential route of androgen receptor 
activation in LNCaP and HepG2 cells (ligand or kinase) is also a worthwhile 
investigation. Only a minority of patients express a mutated androgen receptor phenotype 
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which conveys activation via ligand promiscuity, modeled in the LNCaP cell line. 
However, a majority of prostate cancer patients are found to have increased kinase 
signaling that alternatively activates the receptor [Chen et al., 2004].  
 
Androgen receptor expression is also critical in future analyses because it has been shown 
to be hypersensitive to 5Adiol compared to dihydrotestosterone and testosterone 
[Mizokami et al., 2004]. Impairment of prostate tumor growth in mice has been 
demonstrated when expression of the androgen receptor is knocked down by RNAi [Chen 
et al., 2004]. Moreover, increased expression of the androgen receptor is correlated with 
the elevation in prostate cancer grade; thus, a more aggressive malignancy is linked to 
elevated expression of the receptor [Nishiyama et al., 2007; Wako et al., 2007].  
Furthermore, the androgen receptor has been proposed to play a pivotal role in prostate 
cancer progression to an androgen-independent carcinoma [Umekita et al., 1996]. It was 
demonstrated by Umekita and colleagues that if the LNCaP cell line is grown in 
androgen-depleted medium for a significant amount of time (2 years), the dependency 
upon androgens for growth and survival is lost as the cells transform into a malignancy 
that no longer depends on steroids. This mimics what is seen in men receiving androgen 
ablation therapy, where the amount of circulating androgens is reduced for a period of 
time during which many cases recur as an androgen-independent phenotype. 
Interestingly, however, Umekita et al implanted these androgen-independent LNCaP 
cells into castrated male mice and found that if androgens were administered, the cancer 
regressed. This continued for some time until the cancer later recurred as a hormone-
dependent growth again. These results are fascinating because they suggest that prostate 
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cancer may have the ability to undergo transient dependency upon androgens and 
furthermore, that androgen-independence is simply a misnomer. In combination, these 
studies seem to suggest that the malignancy continues to respond to androgens and that it 
may just simply adapt to its environmental surroundings in order to survive [Chen et al., 
2004; Mizokami et al., 2004; Nishiyama et al., 2007; Umekita et al., 1996; Wako et al., 
2007]. Whether this is accomplished through a modification in the androgen receptor to 
confer a hypersensitivity to the diminished serum/intracellular levels of androgens, an 
upregulation in the expression of the androgen receptor, or the transient death/survival of 
internal populations of cellular clones that vary in their androgen response, this all 
certainly stimulates interest to delve deeper into the complexity of prostate cancer.  
 
If the androgen receptor and PSA expression were to be analyzed in future studies, they 
should be analyzed at both the transcriptional (by real time RT-PCR or northern blots) 
and translational (western blots or immunocytochemistry) levels. Androgen receptor 
expression should also be observed in response to androgen treatment within the HepG2 
cell line as well as IGFR expression in both LNCaP and HepG2 cells. The use of primary 
hepatocyte cultures may also be interesting to study whether benign tissue metabolism of 
androgens elicits the same effects on LNCaP, thus mimicking what would be seen in men 
using these types of supplements who have prostate cancer, but normal liver tissue. 
Finally, no matter whether primary or transformed hepatocellular lines are used, it would 
also be of importance to analyze the regulation, expression, and kinetic parameters of the 
5α-reductases and 17βHSD enzymes in LNCaP and HepG2 cells in response to androgen 
treatment.  
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In conclusion, these results, despite the variability, suggest that the use of nutriceuticals 
marketed as 5Adiol have the potential for disastrous results in men who are at a higher 
risk of developing prostate cancer. The risk of mitogenic effects, especially from small 
levels of unknown compounds in the tested 5Adiol product of this study, raises serious 
questions as to the legitimacy and validity of permitting companies to market and self-
regulate their own products. These questions are further compounded by the documented 
cases of cancer development or neoplastic lesions associated with men who abuse such 
supplements [Alaraj et al., 2005; Bagia et al., 2000; Bryden et al., 1995; Bydder et al., 
2007; Creagh et al., 1988; Froehner et al., 1999; Kafrouni et al., 2007; Martorana et al., 
1999; Overly et al., 1984; Prat et al., 1977; Socas et al., 2005; Velazquez and Alter, 
2004]. In combination with alarming surveys like those completed by Parkinson and 
Evans in 2006, which seek to elucidate current trends in steroid abuse by men, this 
societal problem is not likely to fade anytime soon [Parkinson and Evans, 2006]. 
Furthermore, as doping scandals involving professional athletes continues throughout the 
world (i.e. Mark Maguire, Barry Bonds, and Floyd Landis), the influence of steroid abuse 
on young minds has the potential to expand because of their admiration for athletic role 
models. Education and marketing campaigns are the keys to combating unhealthy use of 
AAS. People from all demographics need to be exposed to the alarming facts of steroid 
use if we are to start to rectify this entirely preventable problem. 
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